These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26752035)

  • 1. [Haute Autorite de sante opinion on cost-effectiveness of health products : results and perspectives].
    Midy F; Raimond V; Thébaut C; Sambuc C; Rumeau-Pichon C
    Sante Publique; 2015; 27(5):691-700. PubMed ID: 26752035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current process and future path for health economic assessment of pharmaceuticals in France.
    Toumi M; Rémuzat C; El Hammi E; Millier A; Aballéa S; Chouaid C; Falissard B
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medico-economic evaluation of healthcare products. Methodology for defining a significant impact on French health insurance costs and selection of benchmarks for interpreting results.
    Dervaux B; Baseilhac E; Fagon JY; ; Biot C; Blachier C; Braun E; Debroucker F; Detournay B; Ferretti C; Granger M; Jouan-Flahault C; Lussier MD; Meyer A; Muller S; Pigeon M; De Sahb R; Sannié T; Sapède C; Vray M
    Therapie; 2014; 69(4):323-8. PubMed ID: 25230355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medico-economic evaluation of health products in the context of the Social Security Financing Act for 2012.
    Dervaux B; Baseilhac E; Fagon JY; ; Ameye V; Angot P; Audry A; Becquemont L; Borel T; Cazeneuve B; Courtois J; Detournay B; Favre P; Granger M; Josseran A; Lassale C; Louvet O; Pinson J; de Pouvourville G; Rochaix L; Rumeau-Pichon C; de Saab R; Schwarzinger M; Sun A
    Therapie; 2013; 68(4):253-63. PubMed ID: 23981264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health.
    Raimond V; Kaltenbach E; Adam C; Lazzarotto S; Le Galès C; Perrier L; Wittwer J
    Bull Cancer; 2021 Dec; 108(12):1162-1169. PubMed ID: 34629167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Assessment of the use by hospital pharmacists of the opinions issued by the Haute Autorité de santé and the economic analysis tools proposed to them].
    Moutier H; Bocquet F; Bourguignon S; Paubel P
    Ann Pharm Fr; 2019 Mar; 77(2):159-167. PubMed ID: 30683487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
    Trouiller JB; Laramée P
    Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FACTORS INFLUENCING REIMBURSEMENT OF MEDICAL DEVICES IN FRANCE.
    Loge P; Delalande F; Reymond MC; Germain S
    Int J Technol Assess Health Care; 2015; 31(6):399-406. PubMed ID: 26868190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The French medecine pricing committee and the medicine economic policy: Rules and competences].
    Giorgi D
    Ann Pharm Fr; 2017 Sep; 75(5):359-372. PubMed ID: 28522031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment.
    Toumi M; Motrunich A; Millier A; Rémuzat C; Chouaid C; Falissard B; Aballéa S
    J Mark Access Health Policy; 2017; 5(1):1344088. PubMed ID: 28804600
    [No Abstract]   [Full Text] [Related]  

  • 12. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
    Schlette S; Hess R
    Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National Authority for Health: France.
    Rochaix L; Xerri B
    Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Health technology assessment and its impact on pharmaceutical pricing and reimbursement policies].
    Castillo-Laborde C; Silva-Illanes N
    Rev Med Chil; 2014 Jan; 142 Suppl 1():S33-8. PubMed ID: 24861178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The transparency committee of the French National Authority for Health].
    Lengliné E
    Bull Cancer; 2024 Feb; 111(2):228-234. PubMed ID: 38176970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convergence of decision rules for value-based pricing of new innovative drugs.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.